An interventional study of Optical Genome Mapping (OGM) and Whole Genome Sequencing (WGS) and Trascriptome analysis in Neurodevelopmental Disorder (Diagnosis), sponsored by IRCCS Eugenio Medea. Recruiting at 1 site in Italy. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by IRCCS Eugenio Medea · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Neurodevelopmental Disorders with a site in Italy — 18 open to participants now, 24 under way, 6 of them phase 3. Neurodevelopmental Disorders · Italy.
Among the 35 studies in Neurodevelopmental Disorders with a site in Italy, this one is the 16th largest by planned enrollment of the 25 interventional ones that give a count, is one of 10 that started in 2024, is one of 18 with no phase, reaches primary completion later than 13 of the 23 other live ones, and was the 24th registered.
355 studies on the registry are indexed under Neurodevelopmental Disorders; 144 are open to participants now.
Browse Neurodevelopmental Disorders studies →18 of the 35 studies in Neurodevelopmental Disorders with a site in Italy are open now. Recruiting first, the newest first:
GRIN Therapeutics, Inc. · Sites in Italy, United States, Australia and 10 more countries
Ages 1 mo–18 yrs
Meyer Children's Hospital IRCCS · Sites in Italy, France, Poland
Ages 2–30
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 8–18
Istituto Giannina Gaslini · Sites in Italy
Ages 28 days+
Istituto Giannina Gaslini · Sites in Italy
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 86 across 218 interventional studies indexed under Neurodevelopmental Disorders.
Median enrollment 80 across the 25 interventional studies, 139 across the 10 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 35 have an industry lead sponsor. The 10 most frequent:
IRCCS Eugenio Medea is the lead sponsor of 109 studies on the registry; 52 are open to participants now.
IRCCS Eugenio Medea has 8 studies filed under Neurodevelopmental Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Neurodevelopmental Disorders with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT07224581Phase 3GRIN Therapeutics, Inc.Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder | 2027-05 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT06851377IRCCS Eugenio MedeaExpanding NGS Data with Optical Genome Mapping (OGM) | 2026-12 |
| NCT07884227Istituto Giannina GasliniMulti-Omics Genetic Investigation Strategies to Enhance the Diagnostic Workflow for Rare Diseases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 35 studies in Neurodevelopmental Disorders with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Over 50% of pediatric neurological and neurodevelopmental disorders lack a molecular diagnosis after standard DNA sequencing and molecular karyotyping. This is due to technical limitations, incomplete variant interpretation, and inadequate genotype-phenotype correlations. New sequencing technologies are crucial for clinical decision-making, offering complete profiles of variants in a patient's DNA to personalize treatment. Optical Genome Mapping (OGM) can detect nearly all structural variants in one experiment. This project aims to use OGM alongside NGS to improve diagnostic yield in 60 children with severe disorders who tested negative for NGS/CMA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
OGM will be used alongside WGS to improve diagnostics in 60 children with severe NDDs lacking a molecular diagnosis after initial CMA and exome analyses.
Genetic: Optical Genome Mapping (OGM) and Whole Genome Sequencing (WGS) · Other: Trascriptome analysis
After identifying causal SVs via OGM, WGS will determine rearrangement breakpoints and examine nearby genes within 100 kb that may have altered expression due to positional effects.
Following genomic characterization results, transcriptome analysis will be performed on patient-derived lymphoblastoid B-cell lines or fibroblasts to investigate the molecular implications of candidate SVs found in the OGM analysis and identify potential transcriptome abnormalities, such as splicing variants, in patients with atypical clinical features.
Genotype-phenotype correlation
Number of pathogenic structural variants found by OGM explaining the phenotype
Time frame: once at recruitment
Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.
Of 142 non-industry interventional studies with no phase under Neurodevelopmental Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 31 months is close to that.
Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 15 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurodevelopmental Disorders →